Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a report published on Monday morning.

OMER has been the topic of several other reports. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, May 13th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, May 16th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Price Performance

Shares of Omeros stock opened at $3.11 on Monday. The business’s 50 day simple moving average is $6.77 and its two-hundred day simple moving average is $8.09. The stock has a market capitalization of $181.33 million, a P/E ratio of -1.35 and a beta of 2.42. Omeros has a one year low of $2.97 and a one year high of $13.60.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). Sell-side analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Omeros by 3.0% in the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock worth $26,610,000 after purchasing an additional 95,599 shares during the period. Nomura Holdings Inc. grew its stake in Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after purchasing an additional 430,932 shares during the period. Two Sigma Investments LP grew its stake in Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after purchasing an additional 13,201 shares during the period. Bank of New York Mellon Corp grew its stake in Omeros by 2.2% in the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 3,321 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Omeros in the fourth quarter worth $1,488,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.